Andrew Thomson is the CEO and co-founder of Modulate Bio, dedicated to developing small molecule medicines for brain disorders. Currently a Blavatnik Fellow in Life Sciences Entrepreneurship at Harvard Business School, Andrew graduated with their MBA in 2024. For five years, Andrew worked as a life sciences consultant at Charles River Associates, leading various strategic projects in biopharma. Andrew's academic background includes a degree in biology from Brown University, where they contributed to the development of a novel technique for building human blood vessels, resulting in four patents and two publications. Additionally, Andrew is a Business Development Partner at Ipsen, focusing on neuroscience and rare diseases.
This person is not in any teams
This person is not in any offices